A DTaP-IPV//PRP∼T vaccine (Pentaxim™): A review of 16 years' clinical experience

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 981-1005

  Plotkin, Stanley A ^a   Liese, Johannes ^b   Madhi, Shabir A ^c   Ortiz, Esteban ^d  

^a University Children's Hospital ^*

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d SANOFI PASTEUR   (France)

Author keywords

effectiveness; immunogenicity; pediatric combination vaccine; pentavalent; Pentaxim; public health; safety

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PENTAXIM; POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANOREXIA; CRYING; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; ETHNICITY; FEVER; HEALTH SURVEY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; IRRITABILITY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SWEDEN; SWELLING; VOMITING;

CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; SWEDEN; TETANUS TOXOID; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 80051516034     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.72     Document Type: Review

References (92)

1. Chandran A, Watt JP, Santosham M. Haemophilus infuenzae vaccines. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offt PA (Eds). Saunders Co., PA, USA, 157-175 (2008).
2. Edwards K, Decker M. Pertussis vaccines. In: Vaccines. 5th edition. Plotkin S, Orenstein W, Offt PA (Eds). Saunders Co., PA, USA 467-517 (2008).
3. Peltola H. Worldwide Haemophilus infuenzae type b disease at the beginning of the 21st Century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. 13(2), 302-317 (2000). (Pubitemid 30205428)
4. Vitek CR, Wharton M. Diptheria toxoid. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offt PA (Eds). Saunders Co., PA, USA 139-155 (2008).
5. Wassilak SG, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Offt PA (Eds). Saunders Co., PA, USA 139-155 (2008).
6. Edwards KM, Decker MD. Combination vaccines: hopes and challenges. Pediatr. Infect. Dis. J. 13(5), 805-839 (1994).
7. Pichichero ME. New combination vaccines. Pediatr. Clin. North Am. 47(2), 407-426 (2000). (Pubitemid 30179948)
8. Obaro SK, Palmer A. Vaccines for children: policies, politics and poverty. Vaccine 21(13-14), 1423-1431 (2003). (Pubitemid 36263184)
9. Andre FE, Booy R, Bock HL et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull. World Health Organ. 86(2), 140-146 (2008). (Pubitemid 351213717)
10. Aristegui J, Usonis V, Coovadia H et al. Facilitating the WHO expanded program of immunization: the clinical profle of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus infuenzae type b vaccine. Int. J. Infect. Dis. 7(2), 143-151 (2003). (Pubitemid 36753521)
11. Decker MD. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr. Infect. Dis. J. 20(11 Suppl.), S10-S18 (2001). (Pubitemid 33055095)
12. Decker M, Bogaerts H, Edwards K. Combination vaccines. In: Vaccines. 5th edition. Plotkin SA, Orenstein W, Of ft PA (Eds). Saunders Co., PA, USA 1069-1101 (2008).
13. Watt JP, Wolfson LJ, O'Brien KL et al. Burden of disease caused by Haemophilus infuenzae type b in children younger than 5 years: global estimates. Lancet 374(9693), 903-911 (2009).
14. World Health Organization. Diphtheria position paper. Wkly Epidemiol. Rec. 81(3), 24-32 (2006).
15. World Health Organization. Tetanus position paper. Wkly Epidemiol. Rec. 81(20), 198-208 (2010).
16. World Health Organization. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol. Rec. 81(15), 137-144 (2006).
17. Centers for Disease Control and Prevention. Recommended childhood immunization schedule-United States, 2001. MMWR 50(1), 1-3 (2001).
18. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR 56(38), 996-1001 (2007).
19. Heymann DL, Sutter RW, Aylward RB. A global call for new polio vaccines. Nature 434(7034), 699-700 (2005). (Pubitemid 40558352)
20. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59, 587-635 (2005). (Pubitemid 41507443)
21. World Health Organization. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol. Rec. 78(28), 241-252 (2003).
22. World Health Organization. Vaccine-derived polioviruses-update. Wkly Epidemiol. Rec. 81(42), 398-404 (2006).
23. Vashishtha VM, Kalra A, John TJ, Thacker N, Agarwal RK. Recommendations of 2nd National Consultative Meeting of Indian Academy of Pediatrics (I AP) on polio eradication and improvement of routine immunization. Indian Pediatr. 45(5), 367-378 (2008). (Pubitemid 351731935)
24. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices. MMWR 49, 1-22 (2000).
25. Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 26(39), 4978-4983 (2008).
26. Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96(3 Pt 2), 557-566 (1995).
27. Pichichero ME, Deloria MA, Rennels MB et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15-to 20-month-old children. Pediatrics 100(5), 772-788 (1997). (Pubitemid 27463312)
28. Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC. An economic evaluation of universal pertussis vaccination in Italy. Vaccine 17(19), 2400-2409 (1999). (Pubitemid 29268363)
29. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997 Arch. Pediatr. Adolesc. Med. 154(8), 797-803 (2000). (Pubitemid 30636627)
30. Tormans G, Van Doorslaer E, Van Damme P, Clara R, Schmitt HJ. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur. J. Pediatr. 157(5), 395-401 (1998). (Pubitemid 28225442)
31. Thisyakorn U, Montellano M, Ortiz E, Lane A. A review of hepatitis B vaccine administration schedules in infants. Presented at: 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 23-26 September 2010.
32. Capeding MR, Cadorna-Carlos J, Book-Montellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP~T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull. World Health Organ. 86(6), 443-451 (2008). (Pubitemid 351821756)
33. Dutta AK, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Immunogenicity and safety of a pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus infuenzae type B conjugate combination vaccine (Pentaxim) with hepatitis B vaccine. Indian Pediatr. 46(11), 975-982 (2009).
34. Madhi SA, Cutland C, Jones S, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaP-IPV//PRP~T booster vaccine in South African infants aged 18 to 19 months. Programs and Abstracts of the 26th International Pediatric Association Congress of Pediatrics. Johannesburg, South Africa (2010).
35. Madhi SA, Cutland C, Jones S, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim™) and monovalent hepatitis B vaccine at 6, 10 and 14 months of age in infants in South Africa. S. Afr. Med. J. 101, 126-131 (2011).
36. Kanra G, Silier T, Yurdakok K et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus infuenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 18(9-10), 947-954 (1999).
37. Li RC, Li FX, Li YP et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus infuenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 29(10), 1913-1920 (2011).
38. Langue J, David T, Roussel F, Pines E, Hoffenbach A. Safety and immunogenicity of DTaP-IPV and Act-Hib vaccines administered either combined or separately to infants at 2, 3, and 4 months of age. Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France (1997).
39. Mallet E, Hoffenbach A, Salomon H, Blondeau C, Fritzell B. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age. Programs and Abstracts of the 14th European Societies for Paediatric Infectious Diseases. Elisnore, Denmark (1996) (Abstract 19).
40. Reinert P, Boucher J, Pines E, Leroux MC, Hoffenbach A, Salomon H. Primary or booster immunization with DTaP-IPV vaccine administered either in combination or in association with Haemophilus infuenzae type b vaccine (Act-Hib): a large-scale safety study Programs and Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases. Paris, France (1997).
41. Lagos R, Kotloff K, Hoffenbach A et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus infuenzae type b conjugate antigens in two-, four-and six-month-old Chilean infants. Pediatr. Infect. Dis. J. 17(4), 294-304 (1998).
42. Mallet E, Fabre P, Pines E et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr. Infect. Dis. J. 19(12), 1119-1127 (2000). (Pubitemid 32003353)
43. Carlsson RM, Claesson BA, Selstam U et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus infuenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr. Infect. Dis. J. 17(11), 1026-1033 (1998). (Pubitemid 28549425)
44. Carlsson RM, Claesson BA, Fagerlund E, Knutsson N, Lundin C. Antibody persistence in fve-year-old children who received a pentavalent combination vaccine in infancy. Pediatr. Infect. Dis. J. 21(6), 535-541 (2002). (Pubitemid 34625835)
45. Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J. Trop. Med. Public Health 40 (2), 282-294 (2009).
46. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Evaluation of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) at 2, 4, and 6 months of age plus hepatitis B vaccine at birth, 2, and 6 months of age in infants in Thailand. Southeast Asian J. Trop. Med. Public Health 41(2), 450-462 (2010).
47. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 93(1), 37-43 (1994). (Pubitemid 24012126)
48. World Health Organization. Pertussis position paper. Wkly Epidemiol. Rec. 85(40), 385-400 (2010).
49. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 112(5), e348 (2003).
50. Collins CL, Salt P, McCarthy N et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22(31-32), 4262-4269 (2004). (Pubitemid 39330349)
51. Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a frst booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 22(11-12), 1406-1414 (2004). (Pubitemid 38446916)
52. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus infuenzae type b (Hib) in 5-6-year-old children after primary vaccination and frst booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 22(11-12), 1415-1422 (2004). (Pubitemid 38446917)
53. Plotkin SA. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17(7), 1055-1065 (2010).
54. Carlsson RM, Trollfors B. Control of pertussis-lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 27(42), 5709-5718 (2009).
55. Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol. Infect. 137(1), 124-130 (2009).
56. World Health Organization. Validation of neonatal tetanus elimination in selected states-India. Wkly Epidemiol. Rec. 83(21), 185-192 (2008).
57. Vidor E, Plotkin SA. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum. Vaccin. 4(5), 328-340 (2008).
58. Dutta A, Verghese VP, Pemde HK, Mathew LG, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity and safety of a DTaP-IPV//PRP~T booster vaccination at 18 to 19 months of age in Indian infants. Programs and Abstracts of the 3rd Asian Pacifc Congress of Pediatrics. Shanghai, China (2009).
59. Li RC, Li FX, Li YP et al. Antibody persistence at 18-20 months of age following primary vaccination of healthy infants with a combined DTaP-IPV//PRP~T vaccine compared to separate vaccines (DTaP, PRP~T and IPV) and immunogenicity and safety of booster vaccination in the Peoples' Republic of China. Programs and Abstracts of the 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan (2010).
60. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118(3), 978-984 (2006). (Pubitemid 46090037)
61. Thisyakorn U, Chotpitayasunondh T, Pancharoen C, Chuenkitmongkol S, Ortiz E. Post-primary vaccination antibody persistence and immunogenicity/safety of a DTaPIPV//PRP~T booster at 18 to 19 months of age in Thai infants. Programs and Abstracts of the 6th Congress of the World Society for Pediatric Infectious Diseases. Buenos Aires, Argentina (2009).
62. Zhang L, Prietsch SOM, Axelsson I, Halperin S. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst. Rev. 1, CD001478 (2011).
63. Jefferson T, Rudin M, Di Pietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21(17-18), 2003-2014 (2003).
64. Desauziers E, Hessel L, Decker MD, Caro JJ, Liese JG. Systematic review of the effects of pertussis vaccines in children. Vaccine 22(21-22), 2681-2684 (2004).
65. Simondon F. Systematic review of the effects of pertussis vaccines in children. Vaccine 22(23-24), 2965 (2004). (Pubitemid 39037195)
66. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a fve-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334(6), 349-355 (1996). (Pubitemid 26049587)
67. Bonmarin I, Levy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill. 12(1), 6 (2007).
68. Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill. 4(12), 128-129 (1999).
69. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr. Infect. Dis. J. 26(9), 806-810 (2007). (Pubitemid 47329851)
70. Liese JG, Stojanov S, Peters A. Duration of effcacy after primary immunisation with Biken acellular pertussis vaccine (Tripedia). Programs and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA (2003).
71. Liese JG, Meschievitz CK, Harzer E et al. Effcacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16(11), 1038-1044 (1997). (Pubitemid 27494960)
72. Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine 24(33-34), 5960-5965 (2006). (Pubitemid 44080365)
73. Hviid A, Stellfeld M, Andersen PH, Wohlfahrt J, Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 22(27-28), 3530-3534 (2004). (Pubitemid 39099630)
74. Hviid A. Post-licensure epidemiology of childhood vaccination: the Danish experience. Expert Rev. Vaccines 5(5), 641-649 (2006). (Pubitemid 46021046)
75. Watanabe M, Nagai M. Acellular pertussis vaccines in Japan: past, present and future. Expert Rev. Vaccines 4(2), 173-184 (2005). (Pubitemid 40525059)
76. Liese JG, Stojanov S, Froeschle J et al. Long term effcacy of Biken acellular pertussis vaccine (Tripedia). Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Toronto, Canada (2000).
77. Bisgard KM, Rhodes P, Connelly BL et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 116(2), e285-e294 (2005). (Pubitemid 44164238)
78. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus infuenzae type b conjugate and diphtheria-tetanus- pertussis containing acellular pertussis. Lancet 354(9195), 2063-2068 (1999).
79. Hoppenbrouwers K, Kanra G, Roelants M et al. Priming effect, immunogenicity and safety of an Haemophilus infuenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. Vaccine 17(7-8), 875-886 (1999). (Pubitemid 29074742)
80. Greenberg DP, Doemland M, Bettinger JA et al. Epidemiology of pertussis and Haemophilus infuenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus infuenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States. Pediatr. Infect. Dis. J. 28(6), 521-528 (2009).
81. Kalies H, Verstraeten T, Grote V et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus infuenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. infuenzae type b combination vaccines in Germany. Pediatr. Infect. Dis. J. 23(10), 944-950 (2004). (Pubitemid 40812782)
82. Schmitt HJ, von Kries R, Hassenpfug B et al. Haemophilus infuenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. infuenzae type b combination vaccines. Pediatr. Infect. Dis. J. 20(8), 767-774 (2001). (Pubitemid 32758019)
83. Cruces RP, Donoso FA, Camacho AJ, Llorente HM. Invasive infections caused by Haemophilus infuenzae type b after the institution of the conjugated vaccine on the expanded programme on immunization in Chile. Rev. Chilena Infectol. 23(1), 50-54 (2006). (Pubitemid 43570002)
84. Kelly DF, Moxon ER, Pollard AJ. Haemophilus infuenzae type b conjugate vaccines. Immunology 113(2), 163-174 (2004). (Pubitemid 39312443)
85. Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill. 11(3), E060302 (2006).
86. Ladhani S, Heath PT, Slack MP et al. Haemophilus infuenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes. Clin. Microbiol. Infect. 16(7), 948-954 (2010).
87. World Health Organization. Haemophilus influenzae type b conjugated vaccines-WHO position paper. Wkly Epidemiol. Rec. 81(47), 445-452 (2006).
88. Garpenholt O, Hugosson S, Fredlund H, Giesecke J, Olcen P. Invasive disease due to Haemophilus infuenzae type b during the frst six years of general vaccination of Swedish children. Acta Paediatr. 89(4), 471-474 (2000). (Pubitemid 30636830)
89. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine 20(9-10), 1316-1330 (2002). (Pubitemid 34131673)
90. Iskedjian M, De Serres G, Einarson TR, Walker JH. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis. Vaccine 28(3), 714-723 (2010).
91. Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, 6 months of age in Thai infants. Int. J. Infect. Dis. 15, e249-e256 (2011).
92. Lee SY, Hwang HS, Kim JH et al. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: A randomized, controlled study in infants in the Republic of Korea. Vaccine 29(8), 1551-1557 (2011).